OM1 and Medtronic Collaborate on Propel Study Examining Long-Term Outcomes for Chronic Rhinosinusitis Patients

Tuesday, April 09, 2024

OM1, a leading company specializing in AI-driven technology and personalized medicine, has released results from its partnership with Medtronic. Together, they investigated the impact of the PROPELTM family of devices – bioabsorbable implants delivering corticosteroids – on patients with chronic rhinosinusitis (CRS) who underwent endoscopic sinus surgery (ESS). The study aimed to demonstrate that the use of PROPEL devices could lead to reduced healthcare resource utilization (HCRU) and fewer surgical revisions post-surgery. This data is intended to facilitate communication with payers and broaden coverage for these implants.

Chronic rhinosinusitis imposes significant financial burdens, estimated at $10-$13 billion annually in the United States alone, due to outpatient visits, prescription therapies, and surgeries. ESS, one of the most common surgical procedures in the US with over 250,000 cases annually, often necessitates additional interventions and medications post-surgery, further increasing costs.

Leveraging OM1's real-world data and a partnership with the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), Medtronic examined the impact of PROPEL devices on HCRU post-ESS. The study compared patients who underwent ESS with PROPEL devices to those who underwent ESS alone. Results indicated that PROPEL devices were associated with decreased HCRU and fewer revision surgeries during the 24-month follow-up period. This suggests that the use of PROPEL devices may result in cost savings for payers by reducing healthcare resource utilization.






Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024